# A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder

> **NCT00892125** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 64 (actual)

## Conditions studied

- Schizophrenia
- Bipolar Disorder

## Interventions

- **DRUG:** paliperidone ER; Carbamazepine

## Key facts

- **NCT ID:** NCT00892125
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892125, "A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00892125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*